Apr 20, 2023 | News
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has completed the dosing portion of the 4-week good laboratory practice (GLP)...
Mar 21, 2023 | News
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new...
Mar 9, 2023 | News
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new...
Feb 24, 2023 | News
Calgary, Alberta – Marvel Biosciences Corp. (“Marvel” or the “Corporation”) announced today that it has completed the closing of the first tranche of the previously announced non-brokered private placement of debentures (“Debentures”) for gross...
Feb 15, 2023 | News
Calgary, Alberta – Marvel Biosciences Corp. (“Marvel” or the “Company”) announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures (“Debentures”) in the principal amount of up to...
Jan 6, 2023 | News
Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices...
